Pregnancy outcome of women transfused during pregnancy with blood products inadvertently obtained from donors treated with acitretin Acitretin and blood transfusions J. Y. Han et al.

Journal of Obstetrics and Gynaecology

Volumn 29, Issue 8, 2009, Pages 694-697

  Han, J Y ^a   Choi, J S ^a   Chun, J M ^b   Park, H D ^c   Lee, S Y ^c   Kim, C H ^d   Park, Q ^e   Nava Ocampo, A A ^f,g,h   Koren, G ^f  

^a Cheil Hospital   (South Korea)

^b Catholic Kwandong University   (South Korea)

^c Sungkwynkwan University

^d Korea Centers for Disease Control and Prevention   (South Korea)

^e Korean Red Cross   (South Korea)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h PharmaReasons   (Canada)

Author keywords

Blood transfusions; Drug safety; Pregnancy outcome; Transplacental exposure

Indexed keywords

ETRETIN; ETRETINATE;

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; FEMALE; GESTATIONAL AGE; HUMAN; LOW BIRTH WEIGHT; PREGNANCY OUTCOME; PRIORITY JOURNAL; SOUTH KOREA;

ACITRETIN; ADULT; BIOLOGICAL PRODUCTS; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; DRUG CONTAMINATION; FEMALE; GESTATIONAL AGE; HALF-LIFE; HUMANS; INFANT, NEWBORN; KERATOLYTIC AGENTS; PREGNANCY; PREGNANCY OUTCOME; PSORIASIS; TERATOGENS;

EID: 70350107369     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443610903177128     Document Type: Article

References (17)

1. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. 2004. Acitretin embryopathy: a case report. Birth defects research. Part A. Clinical and Molecular Teratology 70:831-833.
2. Cohlan SQ. 1954. Congenital anomalies in the rat produced by the excessive intake of vitamin A during pregnancy. Pediatrics 13:556-559.
3. De Leenheer AP, Lambert WE, De Bersaques JP, Kint AH. 1990. High-performance liquid chromatographic determination of etretinate and all-trans- and 13-cis-acitretin in human plasma. Journal of Chromatography 500:637-642.
4. Fantel AG, Shepard TH, Newell-Morris LL, Moffett BC. 1977. Teratogenic effects of retinoic acid in pigtail monkeys (Macaca nemestrina). I. General features. Teratology 15:65-71.
5. Geelen JA. 1979. Hypervitaminosis A induced teratogenesis. CRC Critical Reviews in Toxicology 6:351-375.
6. Geiger JM, Baudin M, Saurat JH. 1994. Teratogenic risk with etretinate and acitretin treatment. Dermatology 189:109-116.
7. Kamm JJ. 1982. Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids. Journal of the American Academy of Dermatology 6:652-659.
8. Koo J, Nguyen Q, Gambla C. 1997. Advances in psoriasis therapy. Advances in Dermatology 12:47-72.
9. Quinnan GV Jr. 1993. Deferral of blood and plasma donors based on medications. Acting Director, Office of Blood Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration. Available at: http:// www.fda.gov/CBER/bldmem/072893.pdf
10. Michel J, Sharon R. 1980. Non-haemolytic adverse reaction after transfusion of a blood unit containing penicillin. British Medical Journal 280:152-153.
11. Park HD, Kim HK, Kim JW, Kim DW, Lee JH, HuhW, et al. 2008. Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions. Transfusion 48:2395-2400.
12. Saurat JH. 1992. Side effects of systemic retinoids and their clinical management. Journal of the American Academy of Dermatology 27:S23-S28.
13. Sharon R, Frutkoff I, Kidroni G, Menczel J. 1982. Applicability and significance of salicylate screening in sera of voluntary blood donors: evaluation of two analytical methods. Journal of Clinical Pathology 35:59-62.
14. Sharon R, Kidroni G, Michel J. Presence of aspirin in blood units. Vox Sanguinis 38:284-287.
15. Stichtenoth DO, Deicher HR, Frö lich JC. 2001. Blood donors on medication. Are deferral periods necessary? European Journal of Clinical Pharmacology 57:433-440.
16. Surber C, Laugier JP, Geiger JM, Bun H, Durand A, Maibach HI. 1992. High-performance liquid chromatography determination of acitretin in plasma and its application to a pharmacokinetic study in human subjects. Pharmaceutical Research 9: 1365-1369.
17. Sturkenboom MC, de Jong-Van Den Berg LT, van Voorst-Vader PC, Cornel MC, Stricker BH, WesselingH. 1994. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. British Journal of Clinical Pharmacology 38:229-235.